Staphylococcal protein A - Protalex
Alternative Names: PRTX-001; PRTX-100Latest Information Update: 28 Jul 2021
At a glance
- Originator Protalex
- Class Antirheumatics; Bacterial proteins; Immunotherapies
- Mechanism of Action B cell inhibitors; Immunomodulators; Macrophage inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Rheumatoid arthritis
- Suspended Idiopathic thrombocytopenic purpura
- No development reported Autoimmune disorders; Myasthenia gravis
Most Recent Events
- 28 Jul 2021 No recent reports of development identified for preclinical development in Myasthenia-gravis in USA (IV, Infusion)
- 15 Apr 2021 No development reported - Phase-I/II for Idiopathic thrombocytopenic purpura in USA, United Kingdom, France (IV)
- 02 Jul 2019 Protalex terminates a phase I/II trial in Idiopathic thrombocytopenic purpura in USA and United Kingdom as enough data had been collected to allow analysis of safety profile and risk-benefit (IV) (NCT02401061)